ArticleFrontiers in aging neuroscience2025
Global burden of Alzheimer's disease and other dementias (1990-2021): inequality, frontier, and decomposition analysis.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From Single-Modal to Multi-Modal Artificial Intelligence in Alzheimer's Disease: A Systematic Review of Databases, Modalities, Diagnostic Performance, and Clinical Translation Challenges.Sensors (Basel, Switzerland) · 2026Pooled it
- Observational
- The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023.Diabetes, obesity & metabolism · 2026Article
- Unravelling the phytochemical complexity of neuroprotective plants: a metabolomics approach to Alzheimer's disease.Molecular biology reports · 2026Review
- Environmental determinants of neurotoxicity: role of heavy metals in neurological disorders.Frontiers in neurology · 2026Review
- Conformationally locked 7-aryl tetrahydroisoquinolines as dual acetylcholinesterase inhibitors and antioxidants: role of intramolecular hydrogen bonding and aryl electronics.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease and other dementias (ADOD) represent a growing global health crisis driven by the rapid aging of the population. Using data from the 2021 Global Burden of Disease (GBD) study, we provide updated global and national estimates of the ADOD burden from 1990 to 2021, quantify key risk factors, and offer evidence to guide resource allocation and prevention strategies. Methods: We analyzed age-standardized incidence, prevalence, mortality, and disability-adjusted life years (DALYs) rates, along with the burden attributable to ADOD-related risk factors. Health disparities were assessed using the slope index of inequality and concentration index. We used frontier analysis to evaluate outcomes relative to development levels. Decomposition analysis identified the drivers of burden changes. Results: Globally, ADOD incidence, prevalence, and mortality increased significantly between 1990 and 2021 (156.54%, 160.81%, and 194.39%, respectively). High fasting blood glucose was the leading modifiable risk factor, contributing to 14.70% of global ADOD mortality, followed by elevated BMI and tobacco use. Burden trends varied across Socio-Demographic Index (SDI) regions, with high-middle SDI regions showing the highest prevalence. Gender-specific risk factor rankings showed high BMI as the second most significant factor in females, while tobacco use ranked second in males but declined over time. Decomposition analysis revealed the greatest increases in DALYs occurred in middle-SDI regions. Discussion: This study reveals a considerable potential to reduce the ADOD burden in many countries. Although some metrics have stabilized or slowed in growth, significant inequalities remain, particularly in lower-SDI nations. Tailored strategies focusing on strengthening healthcare systems, targeting high-risk populations, and improving health education are essential to narrow these gaps. Greater international collaboration and open data sharing are also key to building a life-course management model for ADOD prevention and care, ultimately improving global health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.